Should You Buy Quotient Ltd (QTNT) Stock After it Is Lower By 45.00% in a Week?

Thursday, December 15, 2022 12:55 PM | InvestorsObserver Analysts

Mentioned in this article

Should You Buy Quotient Ltd (QTNT) Stock After it Is Lower By 45.00% in a Week?

The market has been down on Quotient Ltd (QTNT) stock recently. QTNT gets a Bearish score from InvestorsObserver Stock Sentiment Indicator.

Quotient Ltd has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on QTNT!

See Full QTNT Report

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With QTNT Stock Today?

Quotient Ltd (QTNT) stock has gained 5.17% while the S&P 500 is down -2.51% as of 12:53 PM on Thursday, Dec 15. QTNT has risen $0.02 from the previous closing price of $0.32 on volume of 554,763 shares. Over the past year the S&P 500 is lower by -15.95% while QTNT is down -99.56%. QTNT lost -$53.33 per share in the over the last 12 months. To screen for more stocks like Quotient Ltd click here.

More About Quotient Ltd

Quotient Ltd is a commercial-stage diagnostics company. It is involved in the development, manufacturing, and commercialization of conventional reagent products used for blood grouping within the global transfusion diagnostics market. The company develops and commercializes the Mosaiq automation platform. Its product portfolio includes Reagent Red Blood Cells, Antisera Products, Whole Blood Controls, and Ancillary Products. The firm operates in Edinburgh, Scotland, Eysins, Switzerland, and Newton, Pennsylvania. It derives the majority of its revenue from the United States. Click Here to get the full Stock Report for Quotient Ltd stock.